| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -28.8 | -21.5 |
| EPS (diluted, $ a share) | $-0.56 | $-0.88 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ARTV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Artiva Biotherapeutics, Inc.: key numbers
- Share price
- $3.86Close, Nov 17
- Market cap
- $191M
- Shares outstanding
- 49.43MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Artiva Biotherapeutics, Inc.
All →Artiva Biotherapeutics Leadership Change
Elizabeth Hougen resigned from the Board of Directors of Artiva Biotherapeutics as a Class III Director, effective November 11, 2026. The company stated her departure was not due to any disagreement regarding operations, policies, or practices.
Artiva Biotherapeutics Business Update
Artiva Biotherapeutics is implementing a wind-down of its operations, including the discontinuation of its AlloNK cell therapy candidate and a 94% reduction in workforce. The company estimates it will incur $27 million to $35 million in total charges, including up to $15 million for clinical trial close-out and up to $20 million for severance and termination costs. The workforce reduction is expected to be completed in the first quarter of 2027 as the company explores strategic alternatives.
Artiva Biotherapeutics Chief Tech Operations Officer Christopher Horan Sells $43.6K of Stock
Christopher Horan, Chief Tech Operations Officer, sold 10,423 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $43.6K in total on Nov 2, 2026. Shares held after the trade: 302,321 (-3.3%).
- Value
- $43.6K
- Shares
- 10,423
- Price
- $4.18
- Role
- Chief Tech Operations Officer
- Holding change
- -3.3%
- Trade date
- Nov 2, 2026
Artiva Biotherapeutics COO, CLO, Compliance Officer Jennifer Bush Sells $35.3K of Stock
Jennifer Bush, COO, CLO, Compliance Officer, sold 8,439 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $35.3K in total on Nov 2, 2026. Shares held after the trade: 357,720 (-2.3%).
- Value
- $35.3K
- Shares
- 8,439
- Price
- $4.18
- Role
- COO, CLO, Compliance Officer
- Holding change
- -2.3%
- Trade date
- Nov 2, 2026
Artiva Biotherapeutics CEO Fred Aslan Sells $260K of Stock
Fred Aslan, CEO, sold 62,178 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $260K in total on Nov 2, 2026. Shares held after the trade: 1,457,428 (-4.1%).
- Value
- $260K
- Shares
- 62,178
- Price
- $4.18
- Role
- CEO
- Holding change
- -4.1%
- Trade date
- Nov 2, 2026
Artiva Biotherapeutics Business Update
Artiva Biotherapeutics is halting all development of its lead cell therapy candidate AlloNK (AB-101) and implementing a 94% workforce reduction after clinical data failed to meet durability thresholds and two patient deaths occurred. The company has engaged Leerink Partners to explore strategic alternatives, including a potential merger, sale, or liquidation, while reporting a preliminary cash balance of $319.1 million.